In:
Current Drug Targets, Bentham Science Publishers Ltd., Vol. 20, No. 7 ( 2019-05-09), p. 763-774
Abstract:
Owning the high incidence and disability rate in the past decades, to be expected, cardiovascular
diseases (CVDs) have become one of the leading death causes worldwide. Currently, induced pluripotent stem cells (iPSCs), with the potential to form fresh myocardium and improve the functions
of damaged hearts, have been studied widely in experimental CVD therapy. Moreover, iPSC-derived
cardiomyocytes (CMs), as novel disease models, play a significant role in drug screening, drug safety assessment, along with the exploration of pathological mechanisms of diseases. Furthermore, a lot of
studies have been carried out to clarify the biological basis of iPSCs and its derived cells in the treatment of CVDs. Their molecular mechanisms were associated with release of paracrine factors, regulation
of miRNAs, mechanical support of new tissues, activation of specific pathways and specific enzymes, etc. In addition, a few small chemical molecules and suitable biological scaffolds play positive
roles in enhancing the efficiency of iPSC transplantation. This article reviews the development and limitations of iPSCs in CVD therapy, and summarizes the latest research achievements regarding the
application of iPSCs in CVDs.
Type of Medium:
Online Resource
ISSN:
1389-4501
DOI:
10.2174/1389450120666181211164147
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2019
SSG:
15,3
Permalink